Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pneumococcal Disease Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants

NCT04379713
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
1,511 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
41
States / cities
Tucson, Arizona • Fullerton, California • Oxnard, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Jun 10, 2026, 2:32 PM EDT
Completed Not applicable Interventional Results available

Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects

NCT00706550
View directory record Official record
Conditions
HIV Infections
Interventions
(PV) 23-valent pneumococcal polysaccharide vaccine, Placebo
Biological
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Jun 10, 2026, 2:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines

NCT03104075
View directory record Official record
Conditions
Pneumonia, Aging
Interventions
Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein, Pneumococcal Vaccine Polyvalent
Biological
Lead sponsor
The Jackson Laboratory
Other
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Jun 10, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

NCT03313037
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, Prevnar 13, PPSV23, Saline
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
60 Years to 64 Years
Enrollment
444 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
14
States / cities
Anaheim, California • Coral Gables, Florida • DeLand, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2019 · Synced Jun 10, 2026, 2:32 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers

NCT00422292
View directory record Official record
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Meningococcal Polysaccharide Diphtheria Conjugate Vaccine, Measles, Mumps, Rubella and Varicella
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Months to 12 Months
Enrollment
1,664 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
87
States / cities
Tuscaloosa, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Jun 10, 2026, 2:32 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Impact of HIV-1 and Aging on Mucosal Vaccine Responses

NCT03729778
View directory record Official record
Conditions
HIV-1-infection, Human Immunodeficiency Virus, HIV/AIDS, HIV Infections
Interventions
Prevnar-13
Biological
Lead sponsor
VA Eastern Colorado Health Care System
Federal
Eligibility
21 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 14, 2024 · Synced Jun 10, 2026, 2:32 PM EDT
Completed Phase 3 Interventional Results available

Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)

NCT05393037
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
V116, Placebo, PCV15, PPSV23, PCV15 - Part B
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Ft. Pierce, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jun 10, 2026, 2:32 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE)

NCT03950622
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13®
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
1,205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
14
States / cities
Mesa, Arizona • San Diego, California • Hialeah, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Jun 10, 2026, 2:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effectiveness of the Pneumococcal Polysaccharide Vaccine in Military Recruits

NCT02079701
View directory record Official record
Conditions
Pneumonia, Acute Respiratory Disease
Interventions
23-valent pneumococcal vaccine, Placebo
Biological
Lead sponsor
Naval Health Research Center
Federal
Eligibility
Not listed
Enrollment
152,723 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2007
U.S. locations
5
States / cities
San Diego, California • Great Lakes, Illinois • Fort Leonard Wood, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Jun 10, 2026, 2:32 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)

NCT06177912
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
V116, PPSV23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Madera, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jun 10, 2026, 2:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pneumococcal Reference Standard

NCT00479323
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Pneumovax 23
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 25, 2016 · Synced Jun 10, 2026, 2:32 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers

NCT00384397
View directory record Official record
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
249 Days to 305 Days
Enrollment
1,128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
39
States / cities
Montgomery, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Jun 10, 2026, 2:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age

NCT03642847
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Prevnar 13, multivalent pneumococcal conjugate formulation 1, multivalent pneumococcal conjugate formulation 2
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
4
States / cities
Garden Grove, California • Long Beach, California • Honolulu, Hawaii + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Jun 10, 2026, 2:32 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Pneumococcal Post-Vaccination Titers

NCT02726347
View directory record Official record
Conditions
Smokers, Elderly, Asthma, COPD, Recurrent Infections
Interventions
PPV-23
Biological
Lead sponsor
National Jewish Health
Other
Eligibility
19 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Jun 10, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age

NCT03313050
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, Tdap, polysaccharide
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
511 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
18
States / cities
Birmingham, Alabama • Cerritos, California • Savannah, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Jun 10, 2026, 2:32 PM EDT
Completed Phase 3 Interventional

New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)

NCT00035269
View directory record Official record
Conditions
Pneumonia, Pneumococcal, Community Acquired Infections, Gram-positive Bacterial Infections
Interventions
Antibiotic
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
34
States / cities
Los Angeles, California • Jacksonville, Florida • Naples, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2011 · Synced Jun 10, 2026, 2:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of the Immune Response After Vaccination in Multiple Myeloma Patients

NCT02294487
View directory record Official record
Conditions
Multiple Myeloma, Myeloma, Multiple, Myeloma-Multiple
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Jun 10, 2026, 2:32 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2

NCT04887948
View directory record Official record
Conditions
Pneumococcal Disease, COVID-19, SARS-CoV-2 Infection
Interventions
20-valent pneumococcal conjugate vaccine (20vPnC), BNT162b2, Saline
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
570 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
27
States / cities
Anaheim, California • Walnut Creek, California • Coral Gables, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Jun 10, 2026, 2:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Impact of PCV on Disease and Colonization Among Native American Communities

NCT01083459
View directory record Official record
Conditions
Pneumococcal Nasopharyngeal Colonization, Invasive Pneumococcal Disease
Interventions
Not listed
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
7 Months and older
Enrollment
6,628 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Whiteriver, Arizona • Gallup, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 18, 2015 · Synced Jun 10, 2026, 2:32 PM EDT
Completed Phase 4 Interventional Results available

Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines

NCT00993668
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Certolizumab pegol
Other · Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Jun 10, 2026, 2:32 PM EDT
Completed Phase 4 Interventional

PERSPECTIVE: Telithromycin - Acute Exacerbation of Chronic Bronchitis

NCT00132938
View directory record Official record
Conditions
Chronic Bronchitis
Interventions
telithromycin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
35 Years and older
Enrollment
5,660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Jun 10, 2026, 2:32 PM EDT
Completed No phase listed Observational Results available

Effect of Prevnar 13 on Ear Infections in Children

NCT01199016
View directory record Official record
Conditions
Otitis Media
Interventions
Tympanocentesis, Nose/throat swab, Observational
Procedure · Biological
Lead sponsor
Pfizer
Industry
Eligibility
6 Months to 30 Months
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
7
States / cities
Penfield, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Jun 10, 2026, 2:32 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pneumonia Vaccine in Aging HIV Positive Individuals

NCT02558751
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
23-valent pneumococcal polysaccharide vaccine, 13-valent pneumococcal conjugate vaccine
Biological
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
50 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Jun 10, 2026, 2:32 PM EDT
Recruiting Phase 2 Interventional

Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia

NCT05417165
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Pneumococcal 20-valent Conjugate Vaccine, Pneumococcal Polyvalent Vaccine
Biological
Lead sponsor
Seema Bhat
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jun 10, 2026, 2:32 PM EDT